CD30 CAR T Cells for Relapsed Lymphoma (RELY-30)
This study is testing a treatment called CD30 CAR T Cells for people aged 12 to 75 with Hodgkin's Lymphoma or Non-Hodgkin Lymphoma that has come back or not responded to previous treatments. The treatment uses your own infection-fighting T cells, which are specially trained in a lab to recognize and kill lymphoma cells that have a marker called CD30. Researchers will give you one infusion of these modified T cells. The main goal is to see how safe the treatment is by monitoring for side effects (dose-limiting toxicities) for 6 weeks. You must have CD30 positive tumor cells to be eligible.
- Study design
- This is an interventional study with a planned enrollment of 60 participants. It is a dose escalation study, meaning participants will start at one of three different dose levels of CD30 CAR T Cells.
- What's involved
- You will have blood drawn, or undergo a procedure called apheresis to collect your T cells. You will receive one infusion of the modified T cells.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint for safety is measured at 6 weeks after treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
At a glance
Conditions
Where it's being run
2 sites across 1 statesStudy leadership
- Carlos A Ramos, MD · PRINCIPAL_INVESTIGATOR · Baylor College of Medicine
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Number of Patients with Dose-Limiting Toxicities (DLT)6 weeks
Each treated patient will be followed for 6 weeks post the T-cell infusion for the evaluation of DLTs.